Emerging Biomarkers May Complement Early Identification of Autism Traits

Two research approaches are exploring how biological markers might supplement current methods for recognizing autism traits in young children. While not yet diagnostic tools, these developments could help address limitations in existing screening, which relies heavily on behavioral observations that may delay identification for some children.

Urinary Metabolites Show Association with Some Autism Presentations

A 2023 study in Nature Microbiology found that certain gut bacteria-derived compounds in urine were more prevalent among a subgroup of autistic children. These metabolites showed correlation with specific behavioral patterns, though researchers caution they don't indicate causation or apply universally across all autism presentations. The findings suggest potential for future tools that might help match children to tailored supports based on biological profiles.

The findings suggest potential for future tools that might help match children to tailored supports based on biological profiles.

Eye-Tracking Research Progresses Toward Clinical Use

A 2024 JAMA Network Open study found that measuring how infants distribute visual attention between social and non-social stimuli predicted later autism identification with 82% accuracy in research settings. While promising, experts note this predictive validity differs from diagnostic accuracy, and the approach requires further testing before widespread clinical use. The technology currently remains limited to research centers with specialized equipment.

Considerations for Earlier Identification

Recognizing neurodevelopmental differences early—ideally before age 2.5—can help families access supportive services, though the quality and availability of interventions varies significantly. Current screening sometimes misses children whose behavioral presentations differ from common expectations, particularly girls and children from marginalized communities. Researchers hope supplementary biomarkers might eventually help reduce these disparities, though most studies to date lack demographic diversity.

Key Challenges and Ethical Considerations

The field faces several hurdles: autism's natural variability means no single marker will capture all presentations, and some approaches like stool microbiome tests remain in early research phases despite preliminary FDA device designations. Ethical questions also persist about consent, data privacy, and ensuring earlier identification actually leads to meaningful support rather than stigma. Autistic self-advocates emphasize that any screening must center the wellbeing and autonomy of neurodivergent individuals.